EPM Scientific’s Post

🔬 Considering the rapid growth in the biotech industry, leveraging specialist skills is crucial for success. Check out this insightful article, highlighting the 5 key benefits of hiring Life Science Freelancers in Biotech/Pharma. From regulatory affairs to analytical assay development, these experts offer invaluable support for organizations of all sizes. Dive into the details and discover how tapping into the expert economy can propel your biotech endeavors forward! #Biotech #Pharma #LifeScience #ConsultingExperts #CACTUSGlobal 🚀 Read more: https://lnkd.in/g6sbusbu kolabtree.com

I'm working with some STELLAR candidates in Boston and the SF Bay area! They have substantial experience at the intersection of ML and Comp Bio. Whether you are looking for a player/coach team lead or DREAM IC, email Paul.Spencer@PrecisionBioPartners.com to discuss. These folks are ready to take on a new challenge and won't be automating resumes. WE LOVE early-stage companies and are NOT risk averse. Learn more about Precision BioPartners for all your computational hiring needs. #biotech #biotechnology #biotechindustry #biopharma #biopharmaceutical #biopharmaceuticals #pharma #pharmaceutical #pharmaceuticals #startup #startups #strategicadvantage #scienceandtechnology #stem #phd #genetherapy #celltherapy #rnatherapeutics #systemsbiology #ml #ai #drugdiscovery #drugdevelopment #therapeutics #genetherapies #genomics #genomicmedicine #translationalresearch #machinelearning #deeplearning #deeplearningai #generativeai #computationalbiology #bioinformatics #datascience

Are you a 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧-𝐦𝐚𝐤𝐞𝐫 𝐢𝐧 𝐭𝐡𝐞 𝐂𝐃𝐌𝐎 𝐬𝐩𝐚𝐜𝐞?  💊💉 Do you encounter 𝐫𝐨𝐚𝐝𝐛𝐥𝐨𝐜𝐤𝐬 𝐰𝐢𝐭𝐡 𝐲𝐨𝐮𝐫 𝐭𝐞𝐜𝐡𝐧𝐢𝐜𝐚𝐥 𝐡𝐢𝐫��𝐬? Here's where I can help... With extensive experience in sales development for process instruments in the bio/pharmaceutical market, I’ve gained a deep understanding of the development process. I’ve worked with a diverse range of organizations, from multinational CDMOs, to start-ups using CDMO services. I’ve attended key industry conferences, including Bioprocess International and CPHI, staying up-to-date with the latest innovations. My background as a Biomedical Scientist also enables me to truly understand the technical skills you require in the right hire. How many of the CDMO recruitment partners you work with can say they’ve worked on-site with many customers in process development and manufacturing? The global biologics CDMO market is expected to grow 12.3% by 2028 due to a rising demand for cancer treatments, increased outsourcing from pharma and biotech, and the complexity of biologics manufacturing. You need the right people in your organisation to facilitate such growth. I'd love to see how I can help your team. Please drop me a message if you're interested! Follow Harreda for jobs in the global scientific arena. #ExecutiveSearch #CDMO #TechnicalHires #ProcessDevelopment #Biologics #Biopharma #SmallMolecules

🚀 Exciting Next Chapter in the Pharmaceutical World! 🌐 Hello Network! I am thrilled to announce that I have recently graduated with a Master's in Drug Discovery & Safety, specializing in Molecular Pharmacology! 🎓🔬 Throughout my academic journey, I've delved into the fascinating realms of drug development, different analytical techniques, and pharmacological & toxicological research. Now, as I step on this exciting journey into the pharmaceutical industry, I am eager to apply my knowledge and skills to contribute to groundbreaking projects. 💡 I'm reaching out for guidance and opportunities. If you have insights, advice, or potential connections within the pharmaceutical field, I would love to connect and learn from your experiences. 🤝 To my fellow professionals, if you know of any exciting opportunities or have tips to share, I'd be incredibly grateful for your support! Let's connect, collaborate, and make a positive impact together! 🚀 #PharmaceuticalIndustry #DrugDiscovery #Pharmacology #R&D #NewBeginnings #Networking

Pharmacology Graduate | Passionate About Drug Development and Research | Skilled in Data Analysis, Clinical Research, and Regulatory Compliance I am a recent pharmacology graduate with a strong foundation in drug mechanisms, toxicology, and pharmacokinetics. My academic background has equipped me with critical thinking skills, a deep understanding of drug interactions, and the ability to apply these principles in a clinical or research setting. I am passionate about contributing to advancements in healthcare and improving patient outcomes through innovative drug therapies. Key Skills: • Pharmacokinetics and Pharmacodynamics • Clinical Trials and Research Methodology • Regulatory Affairs and Compliance (FDA, EMA) • Data Analysis (SPSS, Excel, Python) • Laboratory Techniques (HPLC, ELISA, Mass Spectrometry) • Medical Writing and Literature Reviews • Team Collaboration and Project Management I am eager to apply my knowledge and skills in a dynamic, research-driven environment and contribute to meaningful breakthroughs in pharmacology and healthcare. Let’s connect if you’re looking for someone who is driven, detail-oriented, and ready to make an impact in the field of pharmacology.

The top R packages for Clinical Biostatistics - list curated by me coming soon! As someone who is in this field (R use in Clinical Research) for almost a decade, i decided to make a list of top 50 R packages based on my opinion. What is factored by me here : 1. My own experience on the use of specific packages. 2. Validation, documentation and the source code 3. The fact that some of the packages are developed by top Pharmaceutical companies and their Statisticians and Data Scientists (not a strict need but a plus). All these factors will play a role in a list i am curating. Will probably start with 20 packages and then expand towards 50 top packages. Stay tuned and feel free to leave your own suggestions, comments too! #datascience #biostatistics #research #clinical #biomedicalresearch #r #rstats #rprogrammer #pharma #company #industry #statisticalprogramming

India's pharmaceutical industry is a major player in the global market, contributing around 20% of the world's supply of generic medicines. The sector is expanding its research and development capabilities, particularly in biotechnology, biosimilars, and Global Capability Centers (GCCs). These GCCs are driving innovation and operational efficiencies, further strengthening the industry's global competitiveness. With robust government support, increasing investments, and technological advancements, India's pharmaceutical industry is set for sustained growth, solidifying its role as a key contributor to global healthcare. https://lnkd.in/dKDCdv_k

📌 From lab to life: Bioinformatics paves the way for accelerated drug development, transforming scientific breakthroughs into real-world treatments. 📌 Drug development timeline overview 📍 Full process takes 10-15 years on average 📍Can vary from <5 years to >20 years 📍Depends on company experience, regulatory demands, medical need etc. 📌Stages and duration 📍Discovery & Preclinical (3-6 years): Identify target, validate, optimize lead compound. 📍IND Application (0.5-2 years): Submit Investigational New Drug application to begin trials. 📍Phase 1 Trials (1-2 years): Test safety and dosage on healthy volunteers 📍Phase 2 Trials (1-3 years): Test efficacy and side effects on patients 📍Phase 3 Trials (2-4 years): Test against current treatments in large populations 📍NDA review (1-2 years): FDA reviews New Drug Application (NDA) 📌FDA approval: Drug hits market 📍High costs 📌 Full development can cost up to $2.6 billion. Key reasons: 📍Long timelines requiring sustained resourcing 📍Expensive tech/instruments and consumables 📍Preclinical studies and clinical trial costs 📍Failures requiring restarting process 📌 Time saving approaches 📍Parallelize processes 📍Repurpose existing drugs 📍Leverage bioinformatics across all stages for efficiencies 📍In summary, drug development involves lengthy and expensive processes. Strategies like leveraging bioinformatics, repurposing drugs and parallelizing development can help accelerate timelines. Thanks for taking the time to read. Happy learning, and feel free to follow for more content! P.S: Let me know your thoughts in the comments section. #bioinformatics #computationalbiology #drugdevelopment #drugdiscovery #repurposingdrugs #fdaapproval #preclinicaltrails #clinicaltrails #clinicalresearch #phasetrails #safety #efficacy #dosage #population #medicalneed #regulatorydemand

🧬 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲: 𝐃𝐍𝐀-𝐄𝐧𝐜𝐨𝐝𝐞𝐝 𝐂𝐡𝐞𝐦𝐢𝐜𝐚𝐥 𝐋𝐢𝐛𝐫𝐚𝐫𝐢𝐞𝐬 (𝐃𝐄𝐋) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬! 🌐💡 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/eKDzHcgs Embark on a journey through the dynamic landscape of DEL technology, where innovation is reshaping the field of drug discovery. Let's uncover key trends and advancements that are propelling the industry forward! 🚀🔍 🌟 Key Highlights: Revolutionizing Drug Discovery: DNA-Encoded Chemical Libraries (DEL) are transforming the way researchers explore chemical space, accelerating drug discovery pipelines. Massive Molecular Diversity: DEL technology enables the synthesis and screening of vast libraries of compounds, offering unprecedented molecular diversity for target engagement. Integrated Chemistry and Biology: Bridging the gap between chemistry and biology, DEL fosters an integrated approach to drug development, enhancing hit identification and optimization. 💡 Market Dynamics: Rapid Adoption: The DEL market is experiencing rapid adoption, driven by the need for efficient and innovative approaches in drug discovery. Pharmaceutical Partnerships: Collaboration between pharmaceutical companies and technology providers is amplifying the impact of DEL platforms on drug development. Accelerated Hit-to-Lead Timelines: DEL accelerates hit identification, shortening the timeline from target validation to lead optimization in drug discovery projects. 🌍 Global Impact: International Collaborations: The global nature of drug discovery sees collaborative efforts using DEL technology, fostering innovation through international partnerships. Biotech and Pharma Engagement: Both biotechnology and pharmaceutical companies actively engage with DEL platforms to enhance their drug discovery capabilities. #Company HotSpot Therapeutics, Inc. X-Chem, Inc. Amgen Life Chemicals Group Elsevier NovAliX BOC Sciences Serengen GmbH BioDuro-Sundia Novartis DyNAbind GmbH HitGen Inc. WuXi AppTec GenScript Pharmaron #Type • Single-pharmacophore • Dual-pharmacophore #Application • Pharmaceutical and Biotechnology Companies • Research Laboratories #DrugDiscovery #DELTechnology #PrecisionMedicine #BiotechInnovation #Pharmaceuticals #AIinDrugDiscovery #LinkedInPos

Shimadzu Corporation and Protein Metrics, LLC Strengthen Agreements to Enhance Data Interoperability — PRBuzz.co — BOSTON, #June #24 #2024 Shimadzu Corporation and #Protein Metrics, LLC have strengthened their agreements to enhance the interoperability of #data benefiting their mutual #customers Through #close cooperation on data #reading capabilities between Byos #products and LabSolutions, Shimadzu and Protein Metrics, LLC further demonstrate their #commitment to GxP and #21 CFR #Part #11 capabilities, data #management and #chain of custody capabilities. "I'm thrilled to #offer integrations between Protein Metrics and Shimadzu #software for our mutual customers," #said #Eric Carlson, #President of Protein Metrics. "Increasingly, customers are #expecting to eliminate data silos and leverage the data they generate to accelerate #decisions This #integration is critical to #help our customers include their biologics characterization data in their #digital transformation efforts." This integration is critical to help our customers include their biologics characterization data in their digital transformation efforts "The collaboration between Shimadzu Corporation and Protein Metrics, LLC will enable us to make significant progress in the quality and multiple attributes of biopharmaceuticals in particular. This characterization requires the interaction of high-resolution mass spectrometry data and the supporting analysis platform to elucidate dynamic structural changes including heterogeneous post-translational modifications. In biopharmaceuticals, there are still unresolved pathways such as in-vivo interactions and biotransformation, and we believe we can contribute to these studies. Furthermore, scientists have learned a lot from the COVID-19 pandemic, and it's one aspect of dramatically progressing in understanding immune systems. The picture of molecular structure using NGS-based deep mass spec and analysis platforms will provide new insights into immunological mechanisms," said Takashi Shimada, Ph.D., Lead Scientist, Structural Biology Technology Research Laboratory, at Shimadzu Corporation. Protein Metrics, LLC continues to advance in providing solutions for biopharmaceutical applications and biologics characterization, enabling raw data to become information ready for AI and ML applications at the point of delivery to users, lab managers, informaticians, and biotherapeutics developers. Details about the industry-leading vendor-neutral biologics characterization software can be found at www.proteinmetrics.com. Shimadzu is a leading worldwide vendor of advanced mass spectrometers with numerous awards for innovation. Their cutting-edge technology and commitment to quality have made them a trusted partner in scientific research and development across various industries.